2023 AUA preview: Dr. Cookson on top research in prostate cancer
Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.
EP: 1.2023 AUA preview: Dr. Cookson on top research in prostate cancer
EP: 2.2023 AUA preview: Dr. Bernie on top research in sexual dysfunction
EP: 3.2023 AUA preview: Dr. Laudano on top research in overactive bladder/incontinence
EP: 4.2023 AUA preview: Dr. Li on top research in bladder cancer
In this video, Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, discusses 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Cookson is professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City.
The following abstracts were previewed:
1. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
2.LBA02-11 (Aggarwal et al): Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)
3. LBA03-03 (Mian et al): Infectious and non-infectious complications following prostate biopsy: a randomized clinical trial
4. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprivation therapy and docetaxel in ARASENS
5. MP29-02 (Shore et al): Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in the North American population from ARASENS
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.
